BREVICON 21-DAY Drug Patent Profile
✉ Email this page to a colleague
When do Brevicon 21-day patents expire, and when can generic versions of Brevicon 21-day launch?
Brevicon 21-day is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in BREVICON 21-DAY is ethinyl estradiol; norethindrone. There is one drug master file entry for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BREVICON 21-DAY?
- What are the global sales for BREVICON 21-DAY?
- What is Average Wholesale Price for BREVICON 21-DAY?
Summary for BREVICON 21-DAY
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Clinical Trials: | 2 |
| Patent Applications: | 219 |
| DailyMed Link: | BREVICON 21-DAY at DailyMed |
Recent Clinical Trials for BREVICON 21-DAY
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
US Patents and Regulatory Information for BREVICON 21-DAY
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | BREVICON 21-DAY | ethinyl estradiol; norethindrone | TABLET;ORAL-21 | 017566-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
